Korean Market
EXCH
Celltrion
★

Celltrion Revises Up Q2 2026 Preliminary Results to Sales of 1.3937 Trillion Won and Operating Profit of 451.8 Billion Won

 
EXCH
Celltrion
★

Celltrion Files Phase 3 Trial Plan for CT-P13 SC in Rheumatoid Arthritis, Expanding Indications Beyond Inflammatory Bowel Disease

 
EXCH
Celltrion
★

Celltrion Files Phase 3 Clinical Trial Plan for CT-P13 SC in US for Rheumatoid Arthritis Aiming to Expand Indications

 
OWNR
Celltrion
★

Celltrion Non-Registered Director Lee Young-nam Disposes All Holdings via Open Market Sales

 
EXCH
Celltrion
★

Celltrion submits European Phase 3 clinical trial application for CT-P13 SC in rheumatoid arthritis, seeking label expansion

 
EXCH
Celltrion
★

Celltrion Submits EU Marketing Authorization Application for CT-P55 Cosentyx Biosimilar

 
OWNR
Celltrion
★

Celltrion Holdings Reports 0.06% Stake Increase in Celltrion and Stock Pledge Rollover and New Borrowings

 
EXCH
Celltrion
★

Celltrion Early Terminates and Voluntarily Withdraws Keytruda Biosimilar Phase 3 Trial in Europe, Highlighting Drug Development Uncertainty

 
EXCH
Celltrion
★

Celltrion Submits Amendment to European Phase 3 Clinical Trial Plan for CT-P44 Darzalex Biosimilar Part 1 and 2 Simultaneously

 
OWNR
Celltrion
★

Celltrion Holdings Boosts Stake in Celltrion by 0.03% to 26.00% via Open Market Purchases

 
OWNR
Celltrion
★

Celltrion Holdings Increases Stake in Celltrion by 0.13% Through Open Market Purchases, Signaling Management Confidence

 
EXCH
Celltrion
★

Celltrion Files Amendment to US Phase 3 Clinical Trial Plan for CT-P51 Keytruda Biosimilar

 
OWNR
Celltrion
★

Celltrion Chairman Seo Jeong-jin Increases Stake to 4.20% via Free Share Acquisition, Minor Ownership Change

 
OWNR
Celltrion
★

Celltrion Unregistered Executive Choi Byeong-uk Acquires 650 Free Shares, Slightly Increasing Holdings

 
OWNR
Celltrion
★

Celltrion Non-Registered Executive Jeon Min-kyung Increases Shareholding by 49 Shares via Free Stock Grant